- 8 Apr 2019 Kymab appoints Simon Sturge as Chief Executive Officer
- 30 Nov 2018 Kymab granted leave to appeal to the UK Supreme Court
- 28 Jun 2018 Kymab and Roche clinical trial agreement for KY1044
- 18 Apr 2018 Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise
- 28 Mar 2018 Kymab statement on UK Court of Appeal’s decision
- 17 Jan 2018 Kymab VP Paul Kellam evidence to House of Lords
- 12 Jan 2018 Kymab ‘top European biotech to watch’ in 2018
- 4 Dec 2017 Anti-PD-L1 antibody KY1003 shows anti-tumour efficacy
- 17 Nov 2017 Kymab makes UK Fast 50 for growth
- 8 Nov 2017 KY1044 strongly inhibits tumour growth in models
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Kymab Announces Presentations at the 24th EHA Annual Congress
Two Company-sponsored oral and poster abstracts to be presented on KY1049 and IntelliSelect® Bispecifics platform
Read article
Featured article: Kymab Poster on Adaptive Phase 1/2 Clinical Trial for KY1044 anti-ICOS Program at 2019 ASCO Meeting
Clinical trial initiated in February 2019 in the U.S., MD Anderson Cancer Center and Sarah Cannon Research Institute Phase ...
Read article